This accounted for 38/351 patients (10.8%) in the prospective cohort (37 CRC patients with activating KRAS or NRAS mutations and one GIST patient with a PDGFRA D842V mutation) and is also an important outcome of tumour testing. The gene discussed is NRAS; the disease is gastrointestinal stromal tumor.